Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial - Top-Institutions - MDSpire

Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial

  • By

  • Mengwei Yan

  • Xiaoying Gu

  • Yeming Wang

  • Bin Cao

  • July 25, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Virology

  • #2

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Immunology
    • Infectious Diseases
    • Antiviral Drug Development

  • #3

    University of Michigan Health System
    University of Michigan Health System

    Ann Arbor, MI

    Key Differentiators

    • Infectious Diseases
    • Clinical Pharmacology
    • Pulmonology

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Virology
    • Clinical Trials

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Clinical Pharmacology
    • Immunology

Original Source(s)

Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial

  • by Mengwei Yan, Xiaoying Gu, Yeming Wang, Bin Cao

  • July 25, 2025

Related Content

Hydrocortisone May Lower Severe CAP Mortality

Network meta-analysis suggests hydrocortisone may offer mortality and ventilation benefits, although evidence certainty remained low.

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing

The Flu Vaccine Face-Off Ends in a Draw

Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season